Springhill Fund Asset Management (HK) Co Ltd
Filing Date
Global Rank
#7,324
/ 7,977
▼ 677
Top Industry
Biotechnology
86.2%
3Y Alpha vs SPY
-24.7%
Period ended 1 year ago
Filed May 14, 2025 · 1y
2 quarters · since Dec 2024
Clone Performance
Feb 2025–Jun 2026 · vs SPYHypothetical growth of cloning every reported 13F position and rebalancing on each filing, indexed to the same start.
Cloned portfolio
-9.8%
SPY
+23.4%
Annualised alpha
-24.7%
Max drawdown
−33.0%
Estimate. 13F holdings are quarter-lagged and long-only, so the clone rebalances about 45 days after each period end — when the filing becomes public — and excludes options and short positions. Past performance does not predict future results.
Portfolio Concentration
16 positions · as of Mar 31, 2025 · Δ vs Dec 31, 2024Top Position
15.2%
+0.6 pts
Top 5
57.9%
−3.3 pts
Top 10
87.2%
−5.3 pts
HHI
922
Diversified−80
Portfolio Trend
2 quarters · across all stocks
Sector Breakdown
As of Mar 31, 2025| Sector | % Portfolio | Value |
|---|---|---|
| Healthcare | 100.0% | $15,769,012 |
Last Quarter's Activity
Export CSVNew Positions
Positions the filer opened this quarter
12 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| SMMT | Summit Therapeutics Inc. | 124,307 | $2,397,882 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 2,600 | $1,648,998 | |
| NBIX | Neurocrine Biosciences Inc | 13,612 | $1,505,487 | |
| JAZZ | Jazz Pharmaceuticals plc | 9,853 | $1,223,249 | |
| ARGX | Argenx SE | 1,146 | $678,277 | |
| LLY | ELI LILLY & Co | 816 | $673,942 | |
| PTGX | Protagonist Therapeutics, Inc | 12,859 | $621,861 | |
| TGTX | Tg Therapeutics, Inc. | 13,500 | $532,305 | |
| TARS | Tarsus Pharmaceuticals, Inc. | 7,076 | $363,494 | |
| ASND | Ascendis Pharma A/S | 2,173 | $338,683 | |
| RYTM | Rhythm Pharmaceuticals, Inc. | 6,277 | $332,492 | |
| BNTX | BioNTech SE | 3,000 | $273,180 | |
| No positions match the current search. | ||||
Sold Out
Positions the filer fully exited
9 positions
| Ticker | Company | Shares | Value | Open |
|---|---|---|---|---|
| LEGN | Legend Biotech Corp | 190,800 | $6,208,632 | |
| CYTK | Cytokinetics Inc | 130,735 | $6,149,774 | |
| VERA | Vera Therapeutics, Inc. | 109,400 | $4,626,526 | |
| CGEM | Cullinan Therapeutics, Inc. | 276,400 | $3,366,552 | |
| DYN | Dyne Therapeutics, Inc. | 131,200 | $3,091,072 | |
| NRIX | Nurix Therapeutics, Inc. | 160,500 | $3,023,820 | |
| DRUG | Bright Minds Biosciences Inc. | 60,648 | $2,184,540 | |
| BCYC | Bicycle Therapeutics PLC | 116,400 | $1,629,600 | |
| ABVX | Abivax S.A. | 207,600 | $1,519,632 | |
| No positions match the current search. | ||||
16 positions ·
$15,769,012 total
· as of Mar 31, 2025
| Ticker | Company | Type | Shares | Value (USD) | % of Portfolio | History |
|---|---|---|---|---|---|---|
| SMMT |
Summit Therapeutics Inc.
Healthcare
|
NEW | 124,307 | $2,397,882 | 15.21% | |
| JANX |
Janux Therapeutics, Inc.
Healthcare
|
Added | 78,500 | $2,119,500 | 13.44% | |
| REGN |
Regeneron Pharmaceuticals, Inc.
Healthcare
|
NEW | 2,600 | $1,648,998 | 10.46% | |
| NBIX |
Neurocrine Biosciences Inc
Healthcare
|
NEW | 13,612 | $1,505,487 | 9.55% | |
| INSM |
INSMED Inc
Healthcare
|
Reduced | 19,192 | $1,464,157 | 9.29% | |
| SLNO |
Soleno Therapeutics Inc
Healthcare
|
Added | 19,858 | $1,418,854 | 9.00% | |
| JAZZ |
Jazz Pharmaceuticals plc
Healthcare
|
NEW | 9,853 | $1,223,249 | 7.76% | |
| ARGX |
Argenx SE
Healthcare
|
NEW | 1,146 | $678,277 | 4.30% | |
| LLY |
ELI LILLY & Co
Healthcare
|
NEW | 816 | $673,942 | 4.27% | |
| PTGX |
Protagonist Therapeutics, Inc
Healthcare
|
NEW | 12,859 | $621,861 | 3.94% | |
| TGTX |
Tg Therapeutics, Inc.
Healthcare
|
NEW | 13,500 | $532,305 | 3.38% | |
| TARS |
Tarsus Pharmaceuticals, Inc.
Healthcare
|
NEW | 7,076 | $363,494 | 2.31% | |
| ASND |
Ascendis Pharma A/S
Healthcare
|
NEW | 2,173 | $338,683 | 2.15% | |
| RYTM |
Rhythm Pharmaceuticals, Inc.
Healthcare
|
NEW | 6,277 | $332,492 | 2.11% | |
| BNTX |
BioNTech SE
Healthcare
|
NEW | 3,000 | $273,180 | 1.73% | |
| COGT |
Cogent Biosciences, Inc.
Healthcare
|
Reduced | 29,491 | $176,651 | 1.12% |